Ado-Trastuzumab Emtansine (Kadcyla) for HER2-Positive Metastatic Breast Cancer

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2013年 / 55卷 / 1425期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：75 / 76
页数：2
相关论文
共 50 条
  • [1] Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer
    Baez-Vallecillo, L.
    Raghavendra, A. Singareeka
    Hess, K.
    Moulder, S. L.
    Tripathy, D.
    Valero, V.
    Murthy, R. K.
    CANCER RESEARCH, 2017, 77
  • [2] FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
    Amiri-Kordestani, Laleh
    Blumenthal, Gideon M.
    Xu, Qiang Casey
    Zhang, Lijun
    Tang, Shenghui W.
    Ha, Linan
    Weinberg, Wendy C.
    Chi, Bo
    Candau-Chacon, Reyes
    Hughes, Patricia
    Russell, Anne M.
    Miksinski, Sarah Pope
    Chen, Xiao Hong
    McGuinn, W. David
    Palmby, Todd
    Schrieber, Sarah J.
    Liu, Qi
    Wang, Jian
    Song, Pengfei
    Mehrotra, Nitin
    Skarupa, Lisa
    Clouse, Kathleen
    Al-Hakim, Ali
    Sridhara, Rajeshwari
    Ibrahim, Amna
    Justice, Robert
    Pazdur, Richard
    Cortazar, Patricia
    CLINICAL CANCER RESEARCH, 2014, 20 (17) : 4436 - 4441
  • [3] Trastuzumab emtansine (Kadcyla®) approval in HER2-positive metastatic breast cancers
    Guerin, Mathilde
    Sabatier, Renaud
    Goncalves, Anthony
    BULLETIN DU CANCER, 2015, 102 (04) : 390 - 397
  • [4] Misconception on the duration of ado-trastuzumab emtansine treatment for HER2-positive early breast cancer
    Chung, Clement
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (10) : 717 - 718
  • [5] Development of trastuzumab emtansine (Kadcyla®) for thetreatment of HER2-positive breast cancer
    Phillips, Gail
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [6] Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
    Spring, Laura M.
    Clark, Shealagh L.
    Li, Tianyu
    Goel, Shom
    Tayob, Nabihah
    Viscosi, Elene
    Abraham, Elizabeth
    Juric, Dejan
    Isakoff, Steven J.
    Mayer, Erica
    Moy, Beverly
    Supko, Jeffrey G.
    Tolaney, Sara M.
    Bardia, Aditya
    NPJ BREAST CANCER, 2021, 7 (01)
  • [7] Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
    Laura M. Spring
    Shealagh L. Clark
    Tianyu Li
    Shom Goel
    Nabihah Tayob
    Elene Viscosi
    Elizabeth Abraham
    Dejan Juric
    Steven J. Isakoff
    Erica Mayer
    Beverly Moy
    Jeffrey G. Supko
    Sara M. Tolaney
    Aditya Bardia
    npj Breast Cancer, 7
  • [8] Changes in the expression of HER2 and other genes in HER2-positive metastatic breast cancer induced by treatment with ado-trastuzumab emtansine and/or pertuzumab/trastuzumab
    Kida, K.
    Lee, J.
    Liu, H.
    Lim, B.
    Murthy, R. K.
    Sahin, A. A.
    Tripathy, D.
    Ueno, N. T.
    CANCER RESEARCH, 2019, 79 (04)
  • [9] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
  • [10] ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer
    Hurvitz, Sara A.
    Bachelot, Thomas
    Bianchini, Giampaolo
    Harbeck, Nadia
    Loi, Sherene
    Park, Yeon Hee
    Prat, Aleix
    Gilham, Leslie
    Boulet, Thomas
    Gochitashvili, Nino
    Monturus, Estefania
    Lambertini, Chiara
    Nyawira, Beatrice
    Knott, Adam
    Restuccia, Eleonora
    Schmid, Peter
    FUTURE ONCOLOGY, 2022, 18 (32) : 3563 - 3572
12345